COLUMBUS, Ohio--(BUSINESS WIRE)--DNA Nanobots, a biotechnology leader in DNA nanoparticles engineered for targeted therapeutics, announced today that Dr. John C. Byrd, M.D., has joined its scientific ...
Backed by NIH, DNA Nanobots aims to disrupt gene therapy with scalable, non-viral platform—$5M round now open to select investors. We're at a pivotal moment, with platform validation and NIH support, ...
Recent advancements in nanotechnology have paved the way for innovative approaches in the fight against cancer. Scientists have unveiled groundbreaking cancer-fighting nanobots, promising a revolution ...